208 related articles for article (PubMed ID: 34672971)
21. [Exploration on the increased sensitivity to docetaxel and reversing mechanism of drug resistance of antisense survivin RNA in gastric cancer cell line SGC7901 cells].
Ma R; Chen XH; Zhang QF; Zhu L; Tang LP; Wang J; Cheng HY; Lei LN
Zhonghua Zhong Liu Za Zhi; 2007 Feb; 29(2):89-92. PubMed ID: 17645838
[TBL] [Abstract][Full Text] [Related]
22. KIT and BRAF heterogeneous mutations in gastrointestinal stromal tumors after secondary imatinib resistance.
Zheng S; Huang KE; Pan YL; Zhou Y; Pan SD; Li X; Jia J; Zheng XL; Tao DY
Gastric Cancer; 2015 Oct; 18(4):796-802. PubMed ID: 25182956
[TBL] [Abstract][Full Text] [Related]
23. Minimal plus-end tracking unit of the cytoplasmic linker protein CLIP-170.
Gupta KK; Paulson BA; Folker ES; Charlebois B; Hunt AJ; Goodson HV
J Biol Chem; 2009 Mar; 284(11):6735-42. PubMed ID: 19074770
[TBL] [Abstract][Full Text] [Related]
24. Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: intrinsic and acquired.
Chien AJ; Moasser MM
Semin Oncol; 2008 Apr; 35(2 Suppl 2):S1-S14; quiz S39. PubMed ID: 18410794
[TBL] [Abstract][Full Text] [Related]
25. Nanoscale drug delivery for taxanes based on the mechanism of multidrug resistance of cancer.
Wang S; Qiu J; Shi Z; Wang Y; Chen M
Biotechnol Adv; 2015; 33(1):224-241. PubMed ID: 25447422
[TBL] [Abstract][Full Text] [Related]
26. Recent advances in the new generation taxane anticancer agents.
Geney R; Chen J; Ojima I
Med Chem; 2005 Mar; 1(2):125-39. PubMed ID: 16787308
[TBL] [Abstract][Full Text] [Related]
27. Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors.
Vrignaud P; Sémiond D; Lejeune P; Bouchard H; Calvet L; Combeau C; Riou JF; Commerçon A; Lavelle F; Bissery MC
Clin Cancer Res; 2013 Jun; 19(11):2973-83. PubMed ID: 23589177
[TBL] [Abstract][Full Text] [Related]
28. Survivin is not induced by novel taxanes.
Sharifi N; Qi J; Bane S; Sharma S; Li R; Robey R; Figg WD; Farrar WL; Kingston DG
Mol Pharm; 2010 Dec; 7(6):2216-23. PubMed ID: 20863081
[TBL] [Abstract][Full Text] [Related]
29. Loss of SLCO1B3 drives taxane resistance in prostate cancer.
de Morrée ES; Böttcher R; van Soest RJ; Aghai A; de Ridder CM; Gibson AA; Mathijssen RH; Burger H; Wiemer EA; Sparreboom A; de Wit R; van Weerden WM
Br J Cancer; 2016 Sep; 115(6):674-81. PubMed ID: 27537383
[TBL] [Abstract][Full Text] [Related]
30. BRCA1 regulates microtubule dynamics and taxane-induced apoptotic cell signaling.
Sung M; Giannakakou P
Oncogene; 2014 Mar; 33(11):1418-28. PubMed ID: 23524581
[TBL] [Abstract][Full Text] [Related]
31. DNA-PKc inhibition overcomes taxane resistance by promoting taxane-induced DNA damage in prostate cancer cells.
Chao OS; Goodman OB
Prostate; 2021 Oct; 81(14):1032-1048. PubMed ID: 34297853
[TBL] [Abstract][Full Text] [Related]
32. SYTL4 downregulates microtubule stability and confers paclitaxel resistance in triple-negative breast cancer.
Liu XY; Jiang W; Ma D; Ge LP; Yang YS; Gou ZC; Xu XE; Shao ZM; Jiang YZ
Theranostics; 2020; 10(24):10940-10956. PubMed ID: 33042263
[No Abstract] [Full Text] [Related]
33. Septin filament coalignment with microtubules depends on SEPT9_i1 and tubulin polyglutamylation, and is an early feature of acquired cell resistance to paclitaxel.
Targa B; Klipfel L; Cantaloube I; Salameh J; Benoit B; Poüs C; Baillet A
Cell Death Dis; 2019 Jan; 10(2):54. PubMed ID: 30670682
[TBL] [Abstract][Full Text] [Related]
34. Epothilones and new analogues of the microtubule modulators in taxane-resistant disease.
Harrison M; Swanton C
Expert Opin Investig Drugs; 2008 Apr; 17(4):523-46. PubMed ID: 18363517
[TBL] [Abstract][Full Text] [Related]
35. Mapping multivalency in the CLIP-170-EB1 microtubule plus-end complex.
Chen Y; Wang P; Slep KC
J Biol Chem; 2019 Jan; 294(3):918-931. PubMed ID: 30455356
[TBL] [Abstract][Full Text] [Related]
36. Secreted frizzled related protein 1 modulates taxane resistance of human lung adenocarcinoma.
Ren J; Wang R; Song H; Huang G; Chen L
Mol Med; 2014 Apr; 20(1):164-78. PubMed ID: 24643460
[TBL] [Abstract][Full Text] [Related]
37. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer.
Darshan MS; Loftus MS; Thadani-Mulero M; Levy BP; Escuin D; Zhou XK; Gjyrezi A; Chanel-Vos C; Shen R; Tagawa ST; Bander NH; Nanus DM; Giannakakou P
Cancer Res; 2011 Sep; 71(18):6019-29. PubMed ID: 21799031
[TBL] [Abstract][Full Text] [Related]
38. Taxanes, microtubules and chemoresistant breast cancer.
McGrogan BT; Gilmartin B; Carney DN; McCann A
Biochim Biophys Acta; 2008 Apr; 1785(2):96-132. PubMed ID: 18068131
[TBL] [Abstract][Full Text] [Related]
39. Stress-induced phosphorylation of CLIP-170 by JNK promotes microtubule rescue.
Henrie H; Bakhos-Douaihy D; Cantaloube I; Pilon A; Talantikite M; Stoppin-Mellet V; Baillet A; Poüs C; Benoit B
J Cell Biol; 2020 Jul; 219(7):. PubMed ID: 32491151
[TBL] [Abstract][Full Text] [Related]
40. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers.
Coleman RL; Broaddus RR; Bodurka DC; Wolf JK; Burke TW; Kavanagh JJ; Levenback CF; Gershenson DM
Gynecol Oncol; 2006 Apr; 101(1):126-31. PubMed ID: 16271384
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
